
EU Risk Management Plan for Caspofungin Fresenius Kabi 50 mg and 70 mg powder for concentrate for solution for infusion

Part VI: Summary of the risk management plan

Summary of risk management plan for Caspofungin Fresenius Kabi 50 mg and 70 mg powder for concentrate for solution for infusion

This is a summary of the risk management plan (RMP) for Caspofungin Fresenius Kabi 50 mg powder for concentrate for solution for infusion and Caspofungin Fresenius Kabi 70 mg powder for concentrate for solution for infusion. The RMP details important risks of Caspofungin Fresenius Kabi 50 mg powder for concentrate for solution for infusion and Caspofungin Fresenius Kabi 70 mg powder for concentrate for solution for infusion, how these risks can be minimised, and how more information will be obtained about Caspofungin Fresenius Kabi 50 mg powder for concentrate for solution for infusion and Caspofungin Fresenius Kabi 70 mg powder for concentrate for solution for infusion's risks and uncertainties (missing information).

Caspofungin Fresenius Kabi 50 mg powder for concentrate for solution for infusion and Caspofungin Fresenius Kabi 70 mg powder for concentrate for solution for infusion's summary of product characteristics (SmPC) and its package leaflet give essential information to healthcare professionals and patients on how Caspofungin Fresenius Kabi 50 mg powder for concentrate for solution for infusion and Caspofungin Fresenius Kabi 70 mg powder for concentrate for solution for infusion should be used.

Important new concerns or changes to the current ones will be included in updates of Caspofungin Fresenius Kabi 50 mg powder for concentrate for solution for infusion and Caspofungin Fresenius Kabi 70 mg powder for concentrate for solution for infusion's RMP.

I. The medicine and what it is used for

Caspofungin Fresenius Kabi 50 mg powder for concentrate for solution for infusion and Caspofungin Fresenius Kabi 70 mg powder for concentrate for solution for infusion is authorised for:

- Treatment of invasive candidiasis in adult or paediatric patients.
- Treatment of invasive aspergillosis in adult or paediatric patients who are refractory to or intolerant of amphotericin B, lipid formulations of amphotericin B and/or itraconazole.

Refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.

- Empirical therapy for presumed fungal infections (such as *Candida* or *Aspergillus*) in febrile, neutropenic adult or paediatric patients.

It contains caspofungin as the active substance and it is given by intravenous infusion.

II. Risks associated with the medicine and activities to minimise or further characterise the risks

Important risks of Caspofungin Fresenius Kabi 50 mg powder for concentrate for solution for infusion and Caspofungin Fresenius Kabi 70 mg powder for concentrate for solution for infusion, together with measures to minimise such risks and the proposed studies for learning more about Caspofungin Fresenius

EU Risk Management Plan for Caspofungin Fresenius Kabi 50 mg and 70 mg powder for concentrate for solution for infusion

Kabi 50 mg powder for concentrate for solution for infusion and Caspofungin Fresenius Kabi 70 mg powder for concentrate for solution for infusion's risks, are outlined below.

Measures to minimise the risks identified for medicinal products can be:

- Specific information, such as warnings, precautions, and advice on correct use, in the package leaflet and SmPC addressed to patients and healthcare professionals;
- Important advice on the medicine's packaging;
- The authorised pack size — the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly;
- The medicine's legal status — the way a medicine is supplied to the patient (e.g. with or without prescription) can help to minimise its risks.

Together, these measures constitute *routine risk minimisation* measures.

In addition to these measures, information about adverse reactions is collected continuously and regularly analysed so that immediate action can be taken as necessary. These measures constitute *routine pharmacovigilance activities*.

II.A List of important risks and missing information

Important risks of Caspofungin Fresenius Kabi 50 mg powder for concentrate for solution for infusion and Caspofungin Fresenius Kabi 70 mg powder for concentrate for solution for infusion are risks that need special risk management activities to further investigate or minimise the risk, so that the medicinal product can be safely administered. Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of Caspofungin Fresenius Kabi 50 mg powder for concentrate for solution for infusion and Caspofungin Fresenius Kabi 70 mg powder for concentrate for solution for infusion. Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g. on the long-term use of the medicine);

List of important risks and missing information	
Important identified risks	None
Important potential risks	None
Missing information	None

II.B Summary of important risks

The safety information in the proposed Product Information is aligned to the reference medicinal product Cancidas.

EU Risk Management Plan for Caspofungin Fresenius Kabi 50 mg and 70 mg powder for concentrate for solution for infusion

II.C Post-authorisation development plan

II.C.1 Studies which are conditions of the marketing authorisation

There are no studies which are conditions of the marketing authorisation or specific obligation of Caspofungin Fresenius Kabi 50 mg powder for concentrate for solution for infusion and Caspofungin Fresenius Kabi 70 mg powder for concentrate for solution for infusion.

II.C.2 Other studies in post-authorisation development plan

There are no studies required for Caspofungin Fresenius Kabi 50 mg powder for concentrate for solution for infusion and Caspofungin Fresenius Kabi 70 mg powder for concentrate for solution for infusion.